NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell of your body and essential for more than 500 enzymatic reactions — most critically, converting food into cellular energy (ATP), repairing damaged DNA, and activating sirtuins, the “longevity proteins” that regulate cellular stress response. NAD+ levels decline roughly 50% between ages 20 and 60, and lower NAD+ is associated with fatigue, mitochondrial dysfunction, and many hallmarks of aging. Restoring NAD+ is one of the most actively researched areas in longevity medicine.

NAD+ is administered as a subcutaneous injection at home. Most protocols begin with a short loading phase (daily or several times per week for 1–2 weeks) followed by a maintenance schedule of 1–3 injections per week based on your provider’s guidance. Unlike IV NAD+ infusions, subcutaneous injections are slower-release and generally better tolerated. Your first shipment includes medication, syringes, alcohol swabs, and step-by-step administration instructions.

Inject slowly. NAD+ can cause temporary flushing, chest or stomach tightness, mild headache, or a rushing sensation if administered too quickly — these effects fade within minutes and are related to speed of infusion, not dose. Most patients describe slight warmth at the injection site and nothing more. After injection, many report a gradual lift in energy, mental clarity, and sleep quality over the following weeks as cellular NAD+ stores rebuild.

Patients most commonly report improved energy, sharper focus, better sleep, faster post-workout recovery, and a general sense of vitality. Clinical research on NAD+ precursors (NR, NMN) has shown measurable increases in blood NAD+ and markers of mitochondrial function. Direct NAD+ supplementation is still an emerging area of research, and individual responses vary based on baseline NAD+ levels, age, and lifestyle. Results may vary.

NAD+ is not recommended during pregnancy or breastfeeding, or for anyone with a known hypersensitivity to NAD+ or the formulation’s excipients. Patients with active cancer should discuss NAD+ therapy with their oncologist before starting, as sirtuin activation and cellular energy pathways can theoretically interact with tumor biology. Always disclose your full medical history and medication list during intake so your provider can make a personalized recommendation.

IV NAD+ drips deliver a high dose in a clinical setting over 2–4 hours, typically at $400–$800 per session, and can be intense (strong flushing, pressure, nausea during the drip). Subcutaneous NAD+ is self-administered at home, far more affordable, and releases more gradually into circulation — which is better tolerated for most patients and fits a consistent maintenance protocol. Both raise NAD+ levels; subcutaneous is the practical choice for ongoing therapy.